The American Gastroenterological Association has issued a Clinical Practice Update on hepatitis delta virus (HDV) management, emphasizing its association with hepatitis B virus (HBV) and the increased risks of cirrhosis and liver cancer. Approximately 30,000 to 60,000 people in the U.S. have active HDV infection, especially prevalent among specific high-risk groups. The AGA recommends universal screening for HDV in chronic HBV patients, beginning with anti-HDV antibody tests. Current treatment options remain limited but promising new therapies are under development to enhance efficacy and safety for HDV patients.

Source: Gastroenterology